510 related articles for article (PubMed ID: 26330291)
21. Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
Xu R; Yuan Z; Yang L; Li L; Li D; Lv C
Oncol Rep; 2017 Sep; 38(3):1767-1773. PubMed ID: 28714034
[TBL] [Abstract][Full Text] [Related]
22. Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells.
Behrouzfar K; Alaee M; Nourbakhsh M; Gholinejad Z; Golestani A
Cell Biochem Funct; 2017 Aug; 35(6):327-333. PubMed ID: 28845527
[TBL] [Abstract][Full Text] [Related]
23. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells.
Zu Y; Liu L; Lee MY; Xu C; Liang Y; Man RY; Vanhoutte PM; Wang Y
Circ Res; 2010 Apr; 106(8):1384-93. PubMed ID: 20203304
[TBL] [Abstract][Full Text] [Related]
24. Effects of 2-deoxyglucose and dehydroepiandrosterone on intracellular NAD(+) level, SIRT1 activity and replicative lifespan of human Hs68 cells.
Yang NC; Song TY; Chen MY; Hu ML
Biogerontology; 2011 Dec; 12(6):527-36. PubMed ID: 21604001
[TBL] [Abstract][Full Text] [Related]
25. Loss of NAMPT in aging retinal pigment epithelium reduces NAD
Jadeja RN; Powell FL; Jones MA; Fuller J; Joseph E; Thounaojam MC; Bartoli M; Martin PM
Aging (Albany NY); 2018 Jun; 10(6):1306-1323. PubMed ID: 29905535
[TBL] [Abstract][Full Text] [Related]
26. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
Grohmann T; Penke M; Petzold-Quinque S; Schuster S; Richter S; Kiess W; Garten A
Leuk Res; 2018 Jun; 69():39-46. PubMed ID: 29653431
[TBL] [Abstract][Full Text] [Related]
28. FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.
Oyarzún AP; Westermeier F; Pennanen C; López-Crisosto C; Parra V; Sotomayor-Flores C; Sánchez G; Pedrozo Z; Troncoso R; Lavandero S
Biochem Pharmacol; 2015 Nov; 98(1):92-101. PubMed ID: 26297909
[TBL] [Abstract][Full Text] [Related]
29. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
[TBL] [Abstract][Full Text] [Related]
30. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
[TBL] [Abstract][Full Text] [Related]
31. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
32. SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence.
Zhang S; Cai G; Fu B; Feng Z; Ding R; Bai X; Liu W; Zhuo L; Sun L; Liu F; Chen X
Mech Ageing Dev; 2012 Jun; 133(6):387-400. PubMed ID: 22561310
[TBL] [Abstract][Full Text] [Related]
33. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
35. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1.
Nakahata Y; Sahar S; Astarita G; Kaluzova M; Sassone-Corsi P
Science; 2009 May; 324(5927):654-7. PubMed ID: 19286518
[TBL] [Abstract][Full Text] [Related]
36. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
37. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
39. Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals.
Li Y; He X; Li Y; He J; Anderstam B; Andersson G; Lindgren U
J Bone Miner Res; 2011 Nov; 26(11):2656-64. PubMed ID: 21812028
[TBL] [Abstract][Full Text] [Related]
40. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor.
Kozako T; Aikawa A; Ohsugi T; Uchida YI; Kato N; Sato K; Ishitsuka K; Yoshimitsu M; Honda SI
Eur J Pharmacol; 2019 Dec; 865():172738. PubMed ID: 31614144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
